Friday, August 30, 2013

Your Invitation to IIR's Business of Biosimilars

Building upon your technical improvements in molecular safety and immunoprofiling, we invite you to join the upcoming 14th Annual Business of Biosimilars on October 15-17 in Boston. The overall characterization of biologics can determine the success of a Biosimilar product, making this is the only event that provides a unique multidisciplinary approach comprising of competitive intelligence, regulatory strategy, bioanalytical comparability, clinical development and more. You will learn from market leaders including Teva, Mylan, Hospira, Sandoz, Momenta, and Boehringer Ingelheim to:

• Navigate the EMEA approval pathway for monoclonal antibodies
• Conduct structural and PK/PD comparability assessments
• Overcome the science and complexity of indication extrapolation
• Define the role of higher order structure in fingerprinting
• Analyze current biosimilar market trends and future challenges

Want to learn more? Download our full agenda.

The 14th Annual Business of Biosimilars and Generic Drugs will take place October 15-17, 2012 in Boston, MA. As a member of the Business of Biosimilars LinkedIn Group, you’ll receive 15% off when you use code XP1886BLOG to register. Have any questions about the event? Feel free to contact Kate Devery at or visit the webpage.

The Business of Biosimilars Team

Business of Biosimilars Webpage
Join our LinkedIn Discussions
Follow Us On Twitter

Share this article with your social network, just click below to share now!

No comments :

Post a Comment